US Government Exercises Option To Buy Additional Doses Of BioCryst's Flu Med

  • The U.S. Department of Health and Human Services (HHS) has exercised its option to purchase an additional 10,000 doses of BioCryst Pharmaceuticals Inc's BCRX Rapivab (peramivir injection)
  • The govt will pay approximately $7 million for the Antiviral influenza therapy. The Rapivab purchase will supply the Strategic National Stockpile.
  • The order is part of a $34.7 million contract the Centers for Disease Control and Prevention awarded in 2018 to procure up to 50,000 doses of Rapivab over five years for the SNS. 
  • With the fulfillment of this new order, BioCryst will have delivered 40,000 doses under the contract.
  • Rapivab is approved in the U.S. for acute uncomplicated influenza in patients six months and older who have been symptomatic for no more than two days. 
  • Price Action: BCRX shares are up 1.57% at $16.17 during the premarket session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechGovernmentNewsHealth CareContractsGeneralBriefsinfluenza
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!